DNA-PK inhibitors have also recently entered clinical trials for AML, and solid cancers (NCT03983824 and NCT03907969), with acceptable toxicity profiles (101, 102) suggesting favorable probability of application in AML therapy. Here, PRKDC is linked to acute myeloid leukemia.